Drug intelligence / Profile preview

BMS-794712

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-794712 is the major N-desmethyl, equipotent metabolite of BMS-791325, a non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor. BMS-794712 exhibits similar plasma pharmacokinetic profiles to its parent compound, with approximately 20–30% of the parent’s exposure. The compound retains equipotent antiviral activity against HCV, making it relevant for consideration of efficacy and drug interactions when BMS-791325 is administered[1][3]. It is likely orally administered as a metabolite generated following dosing of BMS-791325 in clinical trials.

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on BMS-794712.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-794712.

Explore the full profile